tetano
Editor, Senior Moderator
Front Immunol
. 2023 Mar 3;14:1107866.
doi: 10.3389/fimmu.2023.1107866. eCollection 2023.
Characteristics of humoral and cellular responses to coronavirus disease 2019 (COVID-19) inactivated vaccine in central China: A prospective, multicenter, longitudinal study
Youhua Yuan[SUP] 1 [/SUP], Junhong Xu[SUP] 1 [/SUP], Bing Ma[SUP] 1 [/SUP], Guohua Chen[SUP] 2 [/SUP], Zhibin Wang[SUP] 3 [/SUP], Shanmei Wang[SUP] 1 [/SUP], Nan Jing[SUP] 1 [/SUP], Jiangfeng Zhang[SUP] 1 [/SUP], Baoya Wang[SUP] 1 [/SUP], Wenjuan Yan[SUP] 1 [/SUP], Qi Zhang[SUP] 1 [/SUP], Qiongrui Zhao[SUP] 4 [/SUP], Yi Li[SUP] 1 [/SUP]
Affiliations
Abstract
Introduction: In China, the long-term immunogenicity and adverse effects of inactivated vaccines produced by different or the same manufacturer remain unclear. Therefore, the objective of this study was to evaluate the cellular immune responses and neutralizing antibody kinetics of homologous and heterologous administrations of an inactivated coronavirus disease 2019 (COVID-19) vaccine 240 days after the second vaccination.
Methods: This prospective, multicenter, observational, longitudinal study involved 595 participants with a negative SARS-CoV-2 polymerase chain reaction result who were serologically tested and followed for 8 months after vaccination. Neutralizing antibodies, interferon-gamma (IFN-γ), interleukin (IL)-6, CD4+ T-lymphocyte, and B-lymphocyte counts were evaluated in serum samples after stimulation with 2 μg/mL SARS-CoV-2 spike protein for 16 h at follow-up intervals of 2 months.
Results: Most participants [582/595; 146 male participants, 449 female participants; mean age 35 (26-50 years)] rapidly developed neutralizing antibodies after two doses of the vaccine administered 3-weeks apart. The positive rate of neutralizing antibodies peaked at 97.7% at 60-90 days, decreased, and stabilized at 82.9% at 181-240 days post-vaccination. Lower antibody concentrations were correlated with older age, longer duration after vaccination, non-health care workers, mixed-manufacturer vaccinations, and intervals of less than 40 days between two doses of vaccination, whereas lower IFN-γ levels and B-lymphocyte counts were associated with older age, blood type A, and non-health care workers. A higher IL-6 level was associated with older age, mixed-manufacturer vaccinations, intervals of less than 40 days between two doses of vaccination, and medical staff. Adverse reactions were mild or moderate and self-limited, with no serious events reported.
Discussion: Two doses of the Chinese inactivated vaccine induced robust and rapid antibody expression and cellular immune responses. Boosting vaccination is considered important, as antibodies and cellular immune responses were reduced in susceptible populations.
Keywords: COVID-19; cellular immune response; inactive vaccine; kinetics; neutralizing antibody.
. 2023 Mar 3;14:1107866.
doi: 10.3389/fimmu.2023.1107866. eCollection 2023.
Characteristics of humoral and cellular responses to coronavirus disease 2019 (COVID-19) inactivated vaccine in central China: A prospective, multicenter, longitudinal study
Youhua Yuan[SUP] 1 [/SUP], Junhong Xu[SUP] 1 [/SUP], Bing Ma[SUP] 1 [/SUP], Guohua Chen[SUP] 2 [/SUP], Zhibin Wang[SUP] 3 [/SUP], Shanmei Wang[SUP] 1 [/SUP], Nan Jing[SUP] 1 [/SUP], Jiangfeng Zhang[SUP] 1 [/SUP], Baoya Wang[SUP] 1 [/SUP], Wenjuan Yan[SUP] 1 [/SUP], Qi Zhang[SUP] 1 [/SUP], Qiongrui Zhao[SUP] 4 [/SUP], Yi Li[SUP] 1 [/SUP]
Affiliations
- PMID: 36936962
- PMCID: PMC10020218
- DOI: 10.3389/fimmu.2023.1107866
Abstract
Introduction: In China, the long-term immunogenicity and adverse effects of inactivated vaccines produced by different or the same manufacturer remain unclear. Therefore, the objective of this study was to evaluate the cellular immune responses and neutralizing antibody kinetics of homologous and heterologous administrations of an inactivated coronavirus disease 2019 (COVID-19) vaccine 240 days after the second vaccination.
Methods: This prospective, multicenter, observational, longitudinal study involved 595 participants with a negative SARS-CoV-2 polymerase chain reaction result who were serologically tested and followed for 8 months after vaccination. Neutralizing antibodies, interferon-gamma (IFN-γ), interleukin (IL)-6, CD4+ T-lymphocyte, and B-lymphocyte counts were evaluated in serum samples after stimulation with 2 μg/mL SARS-CoV-2 spike protein for 16 h at follow-up intervals of 2 months.
Results: Most participants [582/595; 146 male participants, 449 female participants; mean age 35 (26-50 years)] rapidly developed neutralizing antibodies after two doses of the vaccine administered 3-weeks apart. The positive rate of neutralizing antibodies peaked at 97.7% at 60-90 days, decreased, and stabilized at 82.9% at 181-240 days post-vaccination. Lower antibody concentrations were correlated with older age, longer duration after vaccination, non-health care workers, mixed-manufacturer vaccinations, and intervals of less than 40 days between two doses of vaccination, whereas lower IFN-γ levels and B-lymphocyte counts were associated with older age, blood type A, and non-health care workers. A higher IL-6 level was associated with older age, mixed-manufacturer vaccinations, intervals of less than 40 days between two doses of vaccination, and medical staff. Adverse reactions were mild or moderate and self-limited, with no serious events reported.
Discussion: Two doses of the Chinese inactivated vaccine induced robust and rapid antibody expression and cellular immune responses. Boosting vaccination is considered important, as antibodies and cellular immune responses were reduced in susceptible populations.
Keywords: COVID-19; cellular immune response; inactive vaccine; kinetics; neutralizing antibody.